

New Drug Manufacturer Report

Section	Data element	Field type	Ontruzant	Ontruzant	Renflexis	Maxalt	Maxalt
1. Drug identification	National drug code (11-digit NDC)	Numeric	78206-0147-01	78206-0148-01	78206-0162-01	78206-0142-01	78206-0143-01
	Drug name	Text	Ontruzant 150 mg 1 vial injection	Ontruzant 420 mg 1 vial injection	Renflexis 100 mg solution 1 vial	Maxalt 10 mg Tablets Pale pink	MAXALT-MLT 10 mg Orally Disintegrating Tablets White to off-white
2. Drug Launch Information	Description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally	Text	Marketing: Organon does not currently actively market this product and does not plan to create any marketing efforts in the future; there are no Organon professional representatives detailing this product, nor is Organon sponsoring any medical education or awareness programs involving this product. Pricing: Organon is inheriting the pricing from Merck, Organon is not adjusting WAC prices at time of launch.	Marketing: Organon does not currently actively market this product and does not plan to create any marketing efforts in the future; there are no Organon professional representatives detailing this product, nor is Organon sponsoring any medical education or awareness programs involving this product. Pricing: Organon is inheriting the pricing from Merck, Organon is not adjusting WAC prices at time of launch.	Marketing: Organon does not currently actively market this product and does not plan to create any marketing efforts in the future; there are no Organon professional representatives detailing this product, nor is Organon sponsoring any medical education or awareness programs involving this product. Pricing: Organon is inheriting the pricing from Merck, Organon is not adjusting WAC prices at time of launch.	Marketing: Organon does not currently actively market this product and does not plan to create any marketing efforts in the future; there are no Organon professional representatives detailing this product, nor is Organon sponsoring any medical education or awareness programs involving this product. Pricing: Organon is inheriting the pricing from Merck, Organon is not adjusting WAC prices at time of launch.	Marketing: Organon does not currently actively market this product and does not plan to create any marketing efforts in the future; there are no Organon professional representatives detailing this product, nor is Organon sponsoring any medical education or awareness programs involving this product. Pricing: Organon is inheriting the pricing from Merck, Organon is not adjusting WAC prices at time of launch.
	Estimated volume of patients who may be prescribed the drug	Numeric	639	639	24299	4288.38	4288.38
	Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval	Text	No - neither	No - neither	No - neither	No - neither	No - neither
	Date and price of acquisition if the drug was not developed by the manufacturer	Text	N/A	N/A	N/A	N/A	N/A